Valuation: Orion Oyj

Market Cap 9.56B 10.93B 8.81B 8.1B 15.35B 1,052B 15.62B 105B 41.29B 514B 41.04B 40.14B 1,772B P/E 2026 *
17.4x
P/E 2027 * 14.7x
Enterprise Value 9.45B 10.81B 8.72B 8.02B 15.19B 1,041B 15.45B 104B 40.86B 509B 40.61B 39.72B 1,753B EV / Sales 2026 *
4.54x
EV / Sales 2027 * 3.93x
Free-Float
90.5%
Yield 2026 *
2.81%
Yield 2027 * 3.11%
1 day+1.41%
1 week-3.42%
Current month-5.44%
1 month+1.65%
3 months-7.12%
6 months-2.45%
Current year+7.11%
1 week 67
Extreme 67
70.7
1 month 66
Extreme 66
72.6
Current year 62.3
Extreme 62.3
75.1
1 year 56.3
Extreme 56.3
75.1
3 years 32.5
Extreme 32.5
75.1
5 years 32.5
Extreme 32.5
75.1
10 years 24.75
Extreme 24.75
75.1
Manager TitleAgeSince
Chief Executive Officer 59 31/10/2022
Director of Finance/CFO 50 30/04/2024
Chief Operating Officer 46 31/12/2021
Director TitleAgeSince
Director/Board Member 63 21/03/2017
Director/Board Member 65 21/03/2017
Director/Board Member 66 05/05/2020
Change 5-day change 1-year change 3-year change Capi.($)
+0.30%-3.42% - - 10.93B
-0.12%-5.70%+48.56%+156.40% 1,028B
-2.29%-5.63%+60.19%+56.26% 611B
+1.43%-2.36%+32.40%+83.03% 432B
+0.98%-1.40%+29.49%+23.12% 323B
-0.34%-3.10%+27.00%+43.66% 277B
+1.63%-11.76%+19.72%+23.20% 257B
+3.39%+2.29%-23.68%-38.33% 217B
+0.80%-2.70%+22.41%+57.16% 192B
+1.43%-2.76%+21.09%+70.45% 161B
Average +0.90%-5.24%+26.35%+52.77% 388.7B
Weighted average by Cap. +0.33%-5.52%+35.83%+77.35%

Financials

2026 *2027 *
Net sales 2.08B 2.38B 1.92B 1.76B 3.34B 229B 3.4B 22.92B 8.99B 112B 8.94B 8.74B 386B 2.35B 2.69B 2.17B 2B 3.78B 259B 3.85B 25.93B 10.17B 127B 10.11B 9.89B 436B
Net income 550M 629M 507M 466M 883M 60.48B 898M 6.05B 2.37B 29.56B 2.36B 2.31B 102B 649M 742M 599M 550M 1.04B 71.44B 1.06B 7.15B 2.81B 34.92B 2.79B 2.73B 120B
Net Debt -100M -115M -92.62M -85.14M -161M -11.05B -164M -1.11B -434M -5.4B -431M -422M -18.61B -312M -356M -287M -264M -501M -34.29B -509M -3.43B -1.35B -16.76B -1.34B -1.31B -57.76B
Logo Orion Oyj
Orion Oyj is Finland's leading pharmaceutical group. Net sales break down by family products and services as follows: - innovative medicines (43%): for the treatment of cancer and pain management; - generic, OTC and biosimilar drugs (29.3%); - branded prescription products (16.6%): notably intended for treating dysfunctions of the nervous system, cardiovascular diseases, hormonal and urological treatments; - veterinary products (7.5%); - pharmaceutical ingredients and outsourcing services (3.6%). Net sales break down primarily by source of revenue between sales of products (67.2%) and royalties (23.1%). Net sales are distributed geographically as follows: Finland (19.3%), Scandinavia (10%), Europe (28.1%), North America (25.5%) and other (17.1%).
Employees
4,132
Date Price Change Volume
15/07/26 67.80 +0.30% 2,706
14/07/26 €67.60 -1.60% 6,038
13/07/26 €68.70 -0.87% 3,273
10/07/26 €69.30 -1.56% 3,563
09/07/26 €70.40 +0.28% 4,498
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
67.90EUR
Average target price
74.33EUR
Spread / Average Target
+9.47%

Quarterly revenue - Rate of surprise